Organon & Co. OGN 深 沪
等待开盘 03-26 09:30:00 美东时间
6.10
-0.010
-0.16%
华盛通- 最 高6.23
- 今 开6.22
- 成交量 374.31万股
- 最 低 6.025
- 昨 收 6.11
- 总市值 15.88亿
- 52周最高 13.20
- 市盈率 静 8.51
- 换手率 1.44%
- 52周最低 5.76
- 委 比 41.63%
- 总股本 2.60亿
- 历史最高 36.035
- 量 比 0.84
- 振 幅 3.36%
- 历史最低 5.76
- 每 手 1
- 风险率 1.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多复宏汉霖地舒单抗BILDYOS与TUZEMTY获加拿大卫生部上市批准
2026年3月24日，复宏汉霖（2696.HK）宣布，加拿大卫生部已批准地舒单抗注射液（60 mg/mL）BILDYOS、地舒单抗注射液（120 mg/1.7...
03-24 17:33
Small-cap stocks with mid-range forward P/E list
Small-cap outperformance has narrowed over the last couple of weeks as investor caution increased, with volatility and geopolitical risk weighing on risk appetite and narrowing the performance gap vs....
03-19 02:31
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility
Small-cap outperformance has narrowed over the last couple of weeks as investor caution increased, with volatility and geopolitical risk weighing on risk appetite and narrowing the performance gap vs....
03-19 01:25
Organon trades in red for seven straight sessions
Shares of Organon (OGN) slipped 1.38% to $6.44 in the afternoon trade on Tuesday, adding to six straight sessions of decline. The stock has fallen around 9.2% between March 2 and March 9, compared to ...
03-11 01:52
KDventures to write down remaining Forendo earnout value after Organon halts PCOS drug development
KDventures to write down remaining Forendo earnout value after Organon halts PCOS drug development KDventures AB said Organon has discontinued development of a preclinical drug candidate for polycystic ovary syndrome (PCOS) that was included in Organon’s 2021 acquisition of KDventures’ former portfo
03-03 17:49
KDventures to write off remaining Forendo earnout book value
KDventures to write off remaining Forendo earnout book value KDventures AB said it will write off the entire remaining book value tied to potential additional purchase considerations from Organon’s 2021 acquisition of its former portfolio company Forendo, after Organon discontinued development of Fo
03-03 17:49
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Barclays Maintains Underweight on Organon, Raises Price Target to $8
Barclays analyst Glen Santangelo maintains Organon (NYSE:OGN) with a Underweight and raises the price target from $7.5 to $8.
02-24 22:34
BRIEF-Organon Enters Into Agreement To License Miudella®
BRIEF-Organon Enters Into Agreement To License Miudella® Feb 23 (Reuters) - Organon & Co OGN.N : ORGANON ENTERS INTO AGREEMENT TO LICENSE MIUDELLA®, SEBELA PHARMACEUTICALS’ HORMONE-FREE INTRAUTERINE DEVICE ORGANON & CO - CO TO PAY $27.5 MILLION WITH UP TO $505 MILLION IN MILESTONES Source text: ID:n
02-23 20:36
Organon Licenses Global Rights to Sebela’s MIUDELLA Copper IUD
Organon Licenses Global Rights to Sebela’s MIUDELLA Copper IUD Organon & Co. has agreed to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device for contraception. Organon will pay $27.5 million at closing, with potential sales-based milestone
02-23 20:30
